Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Doxepin Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JB Chemicals Gets USFDA Nod to Market Generic Medication
Details : Doxepin hydrochloride is a psychotropic agent with antidepressant and anxiolytic properties as it binds with high affinity antagonist of histamine H1 receptor and exerts its sleep maintenance effect.
Product Name : Sinequan-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2023
Lead Product(s) : Doxepin Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Loratadine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JB Chemicals Gets USFDA Nod for Generic Product
Details : The USFDA has approved company's abbreviated new drug application (ANDA) for Loratadine tablets USP 10 mg for treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2021
Lead Product(s) : Loratadine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
